Cargando…
Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol
BACKGROUND: Bumetanide is a selective NKCC1 chloride importer antagonist which is being repurposed as a mechanism-based treatment for neurodevelopmental disorders (NDDs). Due to their specific actions, these kinds of interventions will only be effective in particular subsets of patients. To anticipa...
Autores principales: | Geertjens, Lisa, Cristian, Gianina, Haspels, Eva, Ramautar, Jennifer, van der Wilt, Gert Jan, Verhage, Matthijs, Bruining, Hilgo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260985/ https://www.ncbi.nlm.nih.gov/pubmed/35799144 http://dx.doi.org/10.1186/s12888-022-04033-8 |
Ejemplares similares
-
Bumetanide for Irritability in Children With Sensory Processing Problems Across Neurodevelopmental Disorders: A Pilot Randomized Controlled Trial
por: van Andel, Dorinde M., et al.
Publicado: (2022) -
Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study
por: van Andel, Dorinde M., et al.
Publicado: (2020) -
Following Excitation/Inhibition Ratio Homeostasis from Synapse to EEG in Monogenetic Neurodevelopmental Disorders
por: Geertjens, Lisa, et al.
Publicado: (2022) -
Bumetanide As a Candidate Treatment for Behavioral Problems in Tuberous Sclerosis Complex
por: Vlaskamp, Chantal, et al.
Publicado: (2017) -
Bumetanide Effects on Resting-State EEG in Tuberous Sclerosis Complex in Relation to Clinical Outcome: An Open-Label Study
por: Juarez-Martinez, Erika L., et al.
Publicado: (2022)